Casgevy

by | Jan 30, 2024 | Blog, MHRA, NHS

The MHRA is the first Regulatory body in the world to authorise a Crispr-based gene therapy. Casgevy has been authorised for patients over twelve years old who suffer from beta-thalassaemia and sickle cell disease and for whom haematopoietic stem cell transplantation is an appropriate treatment, but a suitable donor is not available. The MHRA approval sets a president in the UK, and the NHS innovative medicine fund should pave the way for eligible patients to receive a treatment for their often painful and life-threatening disease.

Testimonials

The training was delivered in a relaxed and friendly atmosphere. The elements of the training were explained in a clear and concise manner and the course was tailored around your individual requirements. The day was enjoyable and I would not hesitate to use your company again. Tracy Tollervey from CPG – Logistic.
Testimonial from CPG -Logistic trainee